BeiGene expects positive operating income for FY 2025 under US GAAP at J.P. Morgan conference

BeOne Medicines Ltd.

Announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.
Expects to achieve positive operating income for full year 2025 per US GAAP.
Guidance does not assume any new material business development or unusual/non-recurring items.
Replay available on BeiGene's investor website for 30 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.